Author Archive

BPC June 23 updates: INNL Phase 3 data due 3Q or early 4Q. ARGL Phase 2 prelim data due June 30 + CAPR CERU RETA

Jun 24, 2016 No Comments by

Updates to the Company Pipeline Database for June 23, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ARQL 1.92 ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 2 Phase 2 preliminary data due June 30, 2016 at ESMO 18th World Congress on Gastrointestinal Cancer CAPR 4.38 CAP-1002 HOPE-Duchenne Duchenne Muscular Dystrophy (DMD) […]

Daily News Read more

BPC June 22 updates: ARDX Phase 2b ESRD data timeline extended to 1Q 2017. ADMS FDA filing due 2016 + updates for INCY AGEN EPZM

Jun 23, 2016 No Comments by

Updates to the Company Pipeline Database for June 22, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ADMS 16.39 ADS-5102 – EASE LID trial Levodopa-Induced Dyskinesia NDA filing Phase 3 data released December 2015. NDA filing due 2016 AGEN 4.05 INCAGN1876 Solid tumors – cancer Phase 1/2 Phase 1/2 trial […]

Daily News Read more

BPC June 22 updates: GWPH to initiate Phase 3 Infantile spasms trial 4Q + CTRV PBMD PRQR updates

Jun 22, 2016 No Comments by

Updates to the Company Pipeline Database for June 21, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary CTRV 0.97 CMX157 Hepatitis B Phase 2 Phase 2 dosing initiated June 2016. Trial to be completed 4Q 2016 GWPH 87.76 Epidiolex Infantile spasms (IS) Phase 3 Phase 3 to be initiated 4Q […]

Daily News Read more

BPC June 20 updates: OPK receives swift FDA Approval + updates for EPZM FATE GBT OPHT RDHL SGMO TBPH VICL

Jun 21, 2016 No Comments

Updates to the Company Pipeline Database for June 20, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary EPZM 10.96 Tazemetostat Relapsed or refractory B-cell NHL cancer Phase 2 Phase 2 update at the American Society of Hematology (ASH) Meeting on Lymphoma Biology – June 18 2016 FATE 2.00 ProHema Adult […]

Read more

BPC June 17 updates: ARIA initiates rolling NDA. KURA added to database + SMMT EARS MDGN updates

Jun 18, 2016 No Comments

Updates to the Company Pipeline Database for June 17, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary EARS 4.14 AM-111 HEALOS/ASSENT Acute inner ear hearing loss Phase 3 Commenced HEALOS (EU) trial in November 2015.ASSENT trial (US) commenced June 2016. HEALOS data due 2H 2017 MDGN 5.98 NFC-1 – SAGA […]

Read more

BPC June 16 updates: PRTK spikes up 23% after hours following Phase 3 data. SUPN PDUFA delay + updates for AERI BLPH CCXI CRBP KPTI ONCS

Jun 17, 2016 No Comments

Updates to the Company Pipeline Database for June 16, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AERI 18.51 Rhopressa Glaucoma NDA filing NDA filing due 3Q 2016 BLPH 1.98 INOpulse delivery device Pulmonary Arterial Hypertension (PAH) Phase 3 Phase 3 commenced enrolment June 2016 CCXI 4.80 CCX168 Associated vasculitis […]

Read more

BPC June 15 updates: ENDP Adcom scheduled for fall + FLKS initiates Phase 2 MS trial + CTIX update.

Jun 16, 2016 No Comments

Updates to the Company Pipeline Database for June 15, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ENDP 16.82 OPANA ER Management of pain PDUFA Advisory Committee Meeting planned for fall of 2016. PDUFA July 29 2016 will not be met. FLKS 11.22 FLX-787 Multiple Sclerosis Phase 2 Phase 2 […]

Read more

BPC June 14 updates: INFI slides 70% following Phase 2 data release + BPMX update

Jun 15, 2016 No Comments

Updates to the Company Pipeline Database for June 14, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary BPMX 0.77 BPX-03 Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia Phase 3 Phase 3 to be initiated in 2017 INFI 1.36 Duvelisib (IPI-145) DYNAMO Indolent […]

Read more

BPC June 13 updates: KMPH issued CRL. MRNS and RVNC both fail Phase 3 trials + updates for ARGS ARIA FCSC MESO ONCE VICL

Jun 14, 2016 No Comments

Updates to the Company Pipeline Database for June 13, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARGS 5.95 AGS-003 ADAPT Trial Metastatic renal cell carcinoma (mRCC) Phase 3 Third interim analysis June 2016. Overall survival analysis due 1H 2017 ARIA 8.20 Iclusig (ponatinib) – OPTIC-2L Cancer – second line […]

Read more

BPC June 9 updates: KMPH PDUFA delay. SPHS rockets 125% after hours following data release + updates for ALNY ARWR CDTX IRWD OTIC VRX

Jun 09, 2016 No Comments

Updates to the Company Pipeline Database for June 9, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALNY 65.41 ALN-TTRsc02 ATTR amyloidosis Phase 1 Phase 3 to be initiated 2017 assuming positive Phase 1 initial data due end of 2016 ARWR 5.99 ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Phase […]

Read more

BPC June 8 updates: FCSC Phase 2 trial fail. TENX Levosimendan data due 4Q. TRVN Phase 3 Oliceridine data due 1Q + updates for ADXS SCYX TGTX

Jun 09, 2016 No Comments

Updates to the Company Pipeline Database for June 8, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADXS 9.01 Axalimogene filolisbac (FAWCETT) Anal cancer Phase 2 Phase 2 initiated June 2016 FCSC 1.26 azficel-T Chronic Dysphonia Phase 2 Phase 2 endpoints not met – June 2016 SCYX 4.11 SCY-078 Vulvovaginal […]

Read more